Evidence map›Paper›PMID 41161779›Full record

ArticleJournal of clinical and experimental hematopathology : JCEH2025

Triple-hit TdT-positive high-grade B-cell lymphoma mimicking B-lymphoblastic lymphoma and exhibiting immunophenotypic change at relapse.

Akio Saito, Atsushi Isoda, Yukie Terasaki, Hirono Iriuchishima, Masahiro Mihara, Tsukasa Suzuki, Morio Matsumoto, Kennosuke Karube

Abstract readCase Reports
In one paragraph

Article in Journal of clinical and experimental hematopathology : JCEH, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Akio SaitoDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Atsushi IsodaDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Yukie TerasakiDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Hirono IriuchishimaDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Masahiro MiharaDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Tsukasa SuzukiDepartment of Pathology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Morio MatsumotoDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa, Gunma, Japan.
Kennosuke KarubeDepartment of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Terminal deoxynucleotidyl transferase (TdT)-positive high-grade B-cell lymphoma (HGBCL) with MYC and BCL2 and/or BCL6 rearrangements ("double/triple-hit" lymphoma) is a rare, aggressive malignancy that often mimics B-lymphoblastic lymphoma (B-LBL), making accurate diagnosis challenging but clinically critical. We report the case of a 63-year-old female with triple-hit HGBCL involving the duodenum, initially presenting with blastoid morphology and a B-LBL-like immunophenotype: TdT(+), CD10(+), CD20(-), BCL6(-), and CD45dim. However, negativity for CD34 and other features inconsistent with B-LBL, such as MUM-1 positivity and cytoplasmic immunoglobulin expression, were also present. Fluorescence in situ hybridization confirmed MYC, BCL2, and BCL6 rearrangements. Despite an initial response to the hyper-CVAD/MA regimen, the patient subsequently relapsed. Relapse biopsies confirmed persistent triple-hit status and clonal identity via IgH gene rearrangement analysis. Unexpectedly, however, the immunophenotype at relapse had changed significantly, with tumor cells becoming TdT(-), CD20(+), and BCL6(+), while remaining CD10(+). Ultimately, the patient died of the disease despite receiving salvage therapies. To our knowledge, this is the first reported case of TdT-positive HGBCL demonstrating loss of TdT expression alongside other immunophenotypic changes at relapse. This case highlights the potential for significant phenotypic change in this rare HGBCL subtype and the importance of comprehensive immunophenotypic and genetic analysis at both diagnosis and relapse for accurate classification and management, particularly in distinguishing it from B-LBL.

Indexed as

DNA NucleotidylexotransferaseLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaDiagnosis, DifferentialFemaleGene RearrangementHumansImmunophenotypingMiddle AgedProto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mycRecurrenceDNA NucleotidylexotransferaseProto-Oncogene Proteins c-bcl-6Proto-Oncogene Proteins c-mychigh-grade B-cell lymphoma with MYC and BCL2 rearrangementsimmunophenotypic changeTerminal deoxynucleotidyl transferasetriple-hit lymphoma

Identifiers

PMID41161779
PMCPMC12883019

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.